PAVmed Trading Halted Due to Volatility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
PAVmed trading halted, volatility trading pause
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PAVM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PAVM
Wall Street analysts forecast PAVM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAVM is 17.00 USD with a low forecast of 17.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.120
Low
17.00
Averages
17.00
High
17.00
Current: 8.120
Low
17.00
Averages
17.00
High
17.00
About PAVM
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PAVmed Subsidiary Secures VA Contract for EsoGuard Test, Expanding Access to Over 9 Million Veterans
- Contract Approval: Lucid Diagnostics has secured a contract with the Department of Veterans Affairs for its EsoGuard test, significantly enhancing access across the nationwide healthcare system serving over 9 million veterans, thereby strengthening the company's competitive position in the healthcare market.
- Standardized Procurement: The contract allows VA hospitals to procure EsoGuard through a unified framework, ensuring pre-negotiated pricing aligned with Medicare payment standards, which simplifies the procurement process and reduces operational costs.
- Clinical Evidence Support: Lucid stated that the award reflects the clinical evidence supporting the EsoGuard test, further solidifying its potential for integration into standard clinical practice and possibly facilitating collaborations with other integrated health systems.
- Market Performance Analysis: PAVmed shares are currently trading at $11.46, 40.4% above the 20-day simple moving average but 0.8% below the 100-day average, indicating strong short-term performance but potential long-term weakness in market signals.

Continue Reading
Lucid Diagnostics Secures VA Contract for EsoGuard, Boosting PAVmed Stock by 291%
- Contract Approval: Lucid Diagnostics has secured a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access to esophageal precancer testing for over nine million veterans, which is expected to significantly enhance the company's influence in the healthcare market.
- Pricing Advantage: The contract includes pre-negotiated pricing aligned with Medicare payment rates, allowing VA facilities to procure EsoGuard through a streamlined process, further strengthening the product's market competitiveness.
- Stock Performance: PAVmed's stock surged by 291.11% to $17.80 on Wednesday, reflecting strong short-term market performance and aligning with the positive trends in the Nasdaq and S&P 500 indices.
- Technical Indicators: PAVmed is currently trading 167.1% above its 20-day simple moving average, indicating strong short-term technical indicators; although the relative strength index (RSI) is in neutral territory, the MACD shows bullish momentum, suggesting optimistic market sentiment.

Continue Reading





